Mactier R A
Stobhill Hospital, Glasgow, Scotland, U.K.
Adv Perit Dial. 2000;16:223-8.
A variable degree of diffuse peritoneal fibrosis has been documented in all patients who have been on long-term peritoneal dialysis. Peritoneal dialysis-induced diffuse peritoneal fibrosis varies from opacification and "tanning" of the peritoneum, which may have only a moderate detrimental effect on peritoneal transport kinetics, to a progressive, sclerosing encapsulating peritonitis (SEP), which may lead to cessation of peritoneal dialysis and to death. Fewer than 1% of peritoneal dialysis patients develop overt SEP as manifested by combinations of intestinal obstruction, weight loss, and ultrafiltration failure. The diagnosis of SEP depends on a combination of laparotomy and radiological features in suspected cases and consequently the true incidence of SEP is most likely underestimated. Several predisposing, interrelated risk factors for both peritoneal fibrosis and sclerosing encapsulating peritonitis have been identified: prolonged duration of peritoneal dialysis, history of severe or recurrent episodes of peritonitis, and higher exposure to hypertonic glucose-based dialysis solutions. Nevertheless, the etiology of SEP is unknown and several causal factors may simultaneously or sequentially initiate and maintain a low-grade serositis that leads to uncontrolled fibroneogenesis. The high mortality rate of SEP has emphasized the need to develop preventive strategies. These strategies include early peritoneal catheter removal to avoid refractory peritonitis, the development of more biocompatible dialysis solutions, restriction of the use of hypertonic glucose-based dialysis solutions during and after episodes of peritonitis, and, perhaps, limiting the duration of peritoneal dialysis in at-risk patients. This approach was followed in a Japanese unit where a subgroup of all patients who had been on peritoneal dialysis for more than 5 years and who had poor ultrafiltration and peritoneal calcification on computed tomography (CT) scan were shown to have peritoneal sclerosis on peritoneal biopsy and were therefore electively transferred to hemodialysis. This acquired spectrum of peritoneal fibrosing syndromes leads to long-term complications in peritoneal dialysis, whereas localized fibrous adhesions secondary to prior abdominal surgery may prevent the successful initiation of peritoneal dialysis.
所有长期进行腹膜透析的患者均有不同程度的弥漫性腹膜纤维化记录。腹膜透析引起的弥漫性腹膜纤维化程度各异,从腹膜的浑浊和“鞣皮样改变”(这可能对腹膜转运动力学仅有中度不利影响)到进行性硬化性包裹性腹膜炎(SEP),后者可能导致腹膜透析停止甚至死亡。不到1%的腹膜透析患者会出现明显的SEP,表现为肠梗阻、体重减轻和超滤失败等症状。SEP的诊断取决于在疑似病例中结合剖腹手术和放射学特征,因此SEP的实际发病率很可能被低估。已确定了腹膜纤维化和硬化性包裹性腹膜炎的几个相关易感风险因素:腹膜透析时间延长、严重或反复发生腹膜炎病史以及更高程度地接触基于高渗葡萄糖的透析液。然而,SEP的病因尚不清楚,几种致病因素可能同时或相继引发并维持低度浆膜炎,进而导致不受控制的纤维生成。SEP的高死亡率凸显了制定预防策略的必要性。这些策略包括早期拔除腹膜导管以避免难治性腹膜炎、开发生物相容性更好的透析液、在腹膜炎发作期间及之后限制使用基于高渗葡萄糖的透析液,或许还包括限制高危患者的腹膜透析时间。日本的一个医疗单位采用了这种方法,在那里,一组腹膜透析超过5年且计算机断层扫描(CT)显示超滤功能差和腹膜钙化的患者,经腹膜活检显示有腹膜硬化,因此被选择性地转为血液透析。这种获得性腹膜纤维化综合征谱会导致腹膜透析的长期并发症;而既往腹部手术继发的局部纤维粘连可能会妨碍腹膜透析的成功启动。